Skin cancer is a major public health concern in the United States. 1 Melanoma, the third most common type of skin cancer, is diagnosed in over 70 000 individuals and causes more than 9000 deaths each year.
noma incidence rates by 10-year age groups from January 2005 to December 2014; CDC Human Subject institutional review board (IRB) approval was not required for this analysis because the project met the CDC NPCR research analysis requirements, which are approved by the CDC's IRB.
Results | From January 2010 to December 2014, a total of 192 979 melanomas were diagnosed among NHW males 15 years or older, and 131 976 melanomas were diagnosed among NHW females 15 years or older. More than 70% of melanomas were diagnosed among individuals 55 years or older. Melanoma incidence rates among NHW males ranged from 2.0 per 100 000 among those aged 15 to 24 years to 198.3 per 100 000 among those older than 85 years (Table) . Among NHW females, incidence rates ranged from 4.5 per 100 000 among those aged 15 to 24 years to 60.9 among those older than 85 years.
Among both NHW males and females 15 years or older, we observed statistically significant increases in melanoma incidence from January 2005 to December 2014. Among males and females combined and among males only, melanoma incidence decreased significantly among those aged 15 to 24, 25 to 34, and 35 to 44 years and increased significantly among those aged 55 to 64, 65 to 74, 75 to 84, and older than 85 years. Among females only, melanoma incidence decreased significantly among those aged 15 to 24 and 25 to 34 years and increased significantly among those aged 45 to 54, 55 to 64, 65 to 74, 75 to 84, and older than 85 years.
Discussion | Melanoma incidence rates have increased in recent years among NHWs, particularly men older than 54 years and women older than 44 years. In contrast, rates have decreased slightly among younger NHWs (men younger than 45 years and women younger than 35 years). National surveillance data indi- cate that use of indoor tanning, which exposes users to intense levels of UV radiation, and the prevalence of sunburn, a biological indicator of overexposure to UV radiation, have decreased in recent years, particularly among adolescents and young adults. 5, 6 Decreases in indoor tanning and sunburn would be expected to result in decreases in melanoma incidence rates over time. Although primary skin cancer prevention efforts have often focused on children, adolescents, and young adults, the steady increase in melanoma incidence rates among older adults indicates a need for efforts that promote skin cancer preventive behaviors throughout adulthood. Such efforts could focus on groups at high risk, such as outdoor workers and intentional tanners. Ongoing surveillance of melanoma incidence is warranted to monitor progress toward national skin cancer prevention goals and guide prevention strategies.
Variable Response to Naltrexone in Patients With Hailey-Hailey Disease
Hailey-Hailey disease (HHD) is a genetic intraepidermal blistering disorder characterized by chronic macerated erosions in intertriginous areas. 1 The recent report of 2 case series 2, 3 demonstrating the efficacy of low-dose naltrexone in the treatment of HHD represents exciting progress in the management of a disease with limited therapeutic options. Herein we present 3 additional cases of HHD demonstrating varying responses to naltrexone.
Methods | Three patients with biopsy-proven HHD were started on naltrexone based on patient request and followed every 4 to 6 weeks or as needed for physician assessment of clinical response, subjective quality of life, and incidence of adverse effects. This case-report study was granted exemption by the Partners Healthcare institutional review board.
Results | Case 1. A woman in her 30s presented with a 10-year history of HHD. Past treatments included topical steroids and oral antibiotics. The patient was started on naltrexone 4.5 mg nightly, topical clobetasol for flares, and topical tacrolimus for maintenance therapy. After 18 months she experienced 95% clearance of her erosions and ulcerations with relief in pruritus and pain, requiring only minimal amounts of clobetasol.
Case 2.
A woman in her 30s with a 15-year history of HHD poorly responsive to topical antibiotics, antifungals, and steroids, was started on naltrexone 12.5 mg nightly, given the ability to quarter the commercially available 50-mg tablets covered by her insurance. The patient demonstrated complete resolution of erosions and ulcerations within 2 months (Figure) . However, she stopped treatment owing to concerns that 12.5 mg was higher than dosages discussed on HHD online forums. Three weeks later she experienced a flare in the inframammary and inguinal areas and restarted naltrexone at 4.5 mg. After 1 month, she reported that her erosions were improving but at a slower rate than on the 12.5-mg dose.
Case 3. A woman in her 60s with a 17-year history of HHD resistant to topical, intralesional, intramuscular, and systemic steroids, topical antifungals, and oral antibiotics, was started on naltrexone 50 mg nightly, as she also had brachioradialis pruritus. After 1 month, her HHD had neither improved nor worsened, and she was started on acitretin 10 mg daily to improve disease control. The patient experienced 30% clearance in the extent of disease within 1 month. However, she discontinued naltrexone owing to cost, resulting in a flare 2 weeks later. Naltrexone 4.5 mg was started and acitretin increased to 25 mg daily, but her flare progressed over the next 10 days, requiring methylprednisolone, an oral prednisone taper, and
